Business · Companies · 6 hrs ago
Bayer aims to triple India consumer health revenue by 2030
Bayer plans to triple its consumer health revenue in India by 2030.
The German company says India could become its third-largest consumer health market worldwide.
It is assessing products that could help people manage side effects linked to GLP-1 obesity drugs, including constipation, nausea and muscle loss.
Options under consideration include digestive health products, nutrition, multivitamins and supplements.
Bayer says its local team will assess the market before deciding which products to bring to India.
The company also has a network of contract manufacturers in the country.
The plan reflects Bayer’s effort to grow in India, where it says digestive health needs are significant and local competition is strong.
Bayer aims to triple its consumer health revenue in India by 2030.
The company is assessing products that could address side effects of GLP-1 obesity drugs, including constipation, nausea and muscle loss.
Potential product areas include digestive health, nutrition, multivitamins and protein supplements.
Bayer says it will support the Indian team in bringing products to market after it assesses local demand.
The company expects India to become its third-largest consumer health market globally.
- Who
- Bayer AG, including its Consumer Health Division.
- What
- Bayer aims to triple its consumer health business revenue in India by 2030 and is assessing products for GLP-1 drug side effects.
- When
- By 2030.
- Where
- India.
- Why
- Bayer sees growth opportunities in consumer health and products addressing side effects such as constipation, nausea and muscle loss.
This story does not have two clearly opposing sides.
We should be able to triple the India business in terms of the revenue between now and 2030.
Yes. The team is doing an assessment.
This story does not have a timeline yet.
- Revenue target
- Triple India consumer health revenue by 2030
- Potential market rank
- Third-largest consumer health market globally
- Product areas
- Digestive health, nutrition, multivitamins and protein supplements
- GLP-1 side effects mentioned
- Constipation, nausea and muscle loss
- Market assessment
- Bayer's Indian team is assessing products for India
Sources
Related news
RBI Steps Up Rupee Defense as Crude Costs and Outflows Weigh
RBI moves to support the rupee, but longer-term pressure remains
Festive e-commerce sales reach Rs 24,000 crore in two days as VC funding falls
Analyst recommends tracking Glenmark Pharma, Karur Vysya Bank and Go Digit
FMCG sales expected to grow, but rising costs may squeeze margins
Nifty ends losing streak but technical outlook remains weak
HCL Tech set to report Q2 earnings as investors watch growth and guidance
Indian Rupee Rises Offshore After Central Bank Measures
India’s draft steel policy targets 604 million tonnes of capacity by 2047
Indian central bank curbs corporate hedging as rupee weakens
Amundi CIO says Indian equities’ weakness is a temporary pause
